Rapid Micro Biosystems (RPID) EBITDA (2020 - 2026)

Rapid Micro Biosystems (RPID) has 7 years of EBITDA data on file, last reported at -$13.9 million in Q1 2026.

• For the quarter ending Q1 2026, EBITDA fell 18.79% year-over-year to -$13.9 million; the trailing twelve-month figure through Mar 2026 stood at -$49.6 million (down 4.81% YoY), and the FY2025 full-year result was -$47.4 million, up 5.06% from the prior year.
• EBITDA retreated to -$13.9 million in Q1 2026, from -$12.2 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of -$10.2 million in Q4 2024 to a low of -$17.3 million in Q4 2022.
• A 5-year average of -$13.6 million and a median of -$13.9 million in 2026 frame the typical range for EBITDA.
• Across the five-year window, EBITDA plunged 54.77% in 2022 and grew 29.39% in 2023, its largest moves.
• Tracing RPID's EBITDA over 5 years: stood at -$17.3 million in 2022, then climbed by 29.39% to -$12.2 million in 2023, then grew by 16.07% to -$10.2 million in 2024, then declined by 19.38% to -$12.2 million in 2025, then retreated by 13.44% to -$13.9 million in 2026.
• Business Quant data shows RPID's EBITDA at -$13.9 million in Q1 2026, -$12.2 million in Q4 2025, and -$11.4 million in Q3 2025.